Press Releases Foghorn Therapeutics Inc.

Equities

FHTX

US3441741077

Market Closed - Nasdaq Other stock markets 01:30:00 11/05/2024 am IST			5-day change	1st Jan Change
5.56 ^USD	-6.40%		-7.18%	-13.80%

06/05	Foghorn Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
06/05	North American Morning Briefing : Stock Futures -2-	DJ

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Foghorn Therapeutics Provides First Quarter 2024 Financial and Corporate Update	06/05	GL
Foghorn Therapeutics Provides First Quarter 2024 Financial and Corporate Update	06/05	AQ
Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial Officer	16/04	GL
Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs	10/04	GL
Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences	09/04	AQ
Foghorn Therapeutics to Participate in Needham’s 23rd Annual Virtual Healthcare Conference	05/04	GL
Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual Meeting	26/03	GL
Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook	07/03	GL
Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook	07/03	AQ
Foghorn Therapeutics to Present New Preclinical Data at 2024 AACR Annual Meeting, Reflecting Advances with Multiple Potential First-in-Class Medicines, including the Selective Inhibitor of BRM, FHD-909	06/03	GL
Foghorn Therapeutics to Participate in Cowen’s 44th Annual Health Care Conference	28/02	GL
Foghorn Therapeutics to Participate in Cowen’s 44th Annual Health Care Conference	28/02	AQ
Foghorn Provides Pipeline Update on FHD-909 BRM Selective Inhibitor	08/02	GL
Foghorn Therapeutics Highlights Clinical Program Updates and Research Progress and Provides Strategic Objectives for 2024	08/01	GL
Foghorn Therapeutics Announces CFO Departure	04/01	GL
Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286, a Novel BRG1/BRM Inhibitor, in Patients with Advanced Hematologic Malignancies, to be Presented at American Society of Hematology Annual Meeting	01/12	GL
Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286, a Novel BRG1/BRM Inhibitor, in Patients with Advanced Hematologic Malignancies, to be Presented at American Society of Hematology Annual Meeting	01/12	AQ
Foghorn Therapeutics Provides Third Quarter 2023 Financial and Corporate Update	02/11	GL
Foghorn Therapeutics Provides Third Quarter 2023 Financial and Corporate Update	02/11	AQ
Foghorn Therapeutics to Present at Upcoming Conferences Including New Preclinical Data from EP300 and CBP Selective Degrader Programs	24/23/24	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Foghorn Therapeutics Inc.

Equities

FHTX

US3441741077

Press Releases

Filters